Cost-effectiveness model of endoscopic biopsy for eosinophilic esophagitis in patients with refractory GERD

American Journal of Gastroenterology

Volumn 106, Issue 8, 2011, Pages 1439-1445

  Miller, Stephen M ^a   Goldstein, Jay L ^a   Gerson, Lauren B ^b  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUTICASONE; PROTON PUMP INHIBITOR;

ADULT; ARTICLE; COLONOSCOPY; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; ENDOSCOPIC BIOPSY; EOSINOPHILIC ESOPHAGITIS; ESOPHAGEAL PH MONITORING; ESOPHAGUS MANOMETRY; GASTROESOPHAGEAL REFLUX; HEALTH CARE COST; HEALTH CARE DELIVERY; HEALTH CARE QUALITY; HEALTH STATUS; HUMAN; HUMAN TISSUE; LIFE EXPECTANCY; MALE; ORAL BIOPSY; PRIORITY JOURNAL; QUALITY OF LIFE; SENSITIVITY ANALYSIS; TIME; TREATMENT DURATION;

ADULT; ANDROSTADIENES; ANTI-INFLAMMATORY AGENTS; BIOPSY; COHORT STUDIES; COST-BENEFIT ANALYSIS; DECISION SUPPORT TECHNIQUES; DECISION TREES; DEGLUTITION DISORDERS; EOSINOPHILIC ESOPHAGITIS; ESOPHAGOSCOPY; FEMALE; GASTROESOPHAGEAL REFLUX; HUMANS; MALE; MARKOV CHAINS; MIDDLE AGED; PROTON PUMP INHIBITORS; QUALITY OF LIFE; QUALITY-ADJUSTED LIFE YEARS; SENSITIVITY AND SPECIFICITY; SOFTWARE; TIME FACTORS; UNITED STATES;

EID: 79961030341     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2011.94     Document Type: Article

References (40)

1. Straumann A, Simon HU. Eosinophilic esophagitis: escalating epidemiology? J Allergy Clin Immunol 2005; 115: 418-9.
2. Noel RJ, Putnam PE, Rothenberg ME. Eosinophilic esophagitis. N Engl J Med 2004; 351: 940-1.
3. Veerappan GR, Perry JL, Duncan TJ et al. Prevalence of eosinophilic esophagitis in an adult population undergoing upper endoscopy: a prospective study. Clin Gastroenterol Hepatol 2009, 420-6, 426 e1-2.
4. Kapel RC, Miller JK, Torres C et al. Eosinophilic esophagitis: a prevalent disease in the United States that affects all age groups. Gastroenterology 2008; 134: 1316-21. (Pubitemid 351615360)
5. Modlin I, Kidd M. GERD 2004: issues from the past and a consensus for the future. Best Pract Res Clin Gastroenterol 2004; 18 (Suppl): 55-66. (Pubitemid 39654790)
6. Korner T, Schutze K, van Leendert RJ et al. Comparable efficacy of pantoprazole and omeprazole in patients with moderate to severe reflux esophagitis. Results of a multinational study. Digestion 2003; 67: 6-13. (Pubitemid 36570296)
7. Furuta GT, Liacouras CA, Collins MH et al. Eosinophilic esophagitis in children and adults: a systematic review and consensus recommendations for diagnosis and treatment. Gastroenterology 2007; 133: 1342-63.
8. Kahrilas PJ, Shaheen NJ, Vaezi MF. American Gastroenterological Association Institute technical review on the management of gastroesophageal reflux disease. Gastroenterology 2008; 135: 1392-413, 1413 e1-5.
9. Straumann A, Spichtin HP, Grize L et al. Natural history of primary eosinophilic esophagitis: a follow-up of 30 adult patients for up to 11.5 years. Gastroenterology 2003; 125: 1660-9. (Pubitemid 37500430)
10. Muller S, Puhl S, Vieth M et al. Analysis of symptoms and endoscopic findings in 117 patients with histological diagnoses of eosinophilic esophagitis. Endoscopy 2007; 39: 339-44. (Pubitemid 46605933)
11. Straumann A, Spichtin HP, Bernoulli R et al. Idiopathic eosinophilic esophagitis: a frequently overlooked disease with typical clinical aspects and discrete endoscopic findings. Schweiz Med Wochenschr 1994; 124: 1419-29. (Pubitemid 24267319)
12. Russell LB, Gold MR, Siegel JE et al. The role of cost-effectiveness analysis in health and medicine. Panel on cost-effectiveness in health and medicine. JAMA 1996; 276: 1172-7. (Pubitemid 26329746)
13. Luce B, Manning WG, Siegel JE. Estimating costs in cost-effectiveness analyses. Oxford University Press: New York, NY, 1996.
14. Richter JE, Bochenek W. Oral pantoprazole for erosive esophagitis: a placebo-controlled, randomized clinical trial. Pantoprazole US GERD Study Group. Am J Gastroenterol 2000; 95: 3071-80.
15. Dean BB, Gano Jr AD, Knight K et al. Effectiveness of proton pump inhibitors in nonerosive reflux disease. Clin Gastroenterol Hepatol 2004; 2: 656-64. (Pubitemid 39013424)
16. Rodrigo S, Abboud G, Oh D et al. High intraepithelial eosinophil counts in esophageal squamous epithelium are not specific for eosinophilic esophagitis in adults. Am J Gastroenterol 2008; 103: 435-42. (Pubitemid 351248715)
17. Gonsalves N, Policarpio-Nicolas M, Zhang Q et al. Histopathologic variability and endoscopic correlates in adults with eosinophilic esophagitis. Gastrointest Endosc 2006; 64: 313-9. (Pubitemid 44233586)
18. Dellon ES, Gibbs WB, Fritchie KJ et al. Clinical, endoscopic, and histologic findings distinguish eosinophilic esophagitis from gastroesophageal reflux disease. Clin Gastroenterol Hepatol 2009; 7: 1305-13; quiz 1261.
19. Kanakala V, Lamb CA, Haigh C et al. The diagnosis of primary eosinophilic oesophagitis in adults: missed or misinterpreted? Eur J Gastroenterol Hepatol 2010; 22: 848-55.
20. Arias E. United States life tables, 2006. National vital statistics reports; vol 58 no 21. Hyattsville, MD: National Center for Health Statistics, 2010.
21. Fass R, Shapiro M, Dekel R et al. Systematic review: proton-pump inhibitor failure in gastro-oesophageal reflux disease-where next? Aliment Pharmacol Ther 2005; 22: 79-94. (Pubitemid 41039696)
22. Desai TK, Stecevic V, Chang CH et al. Association of eosinophilic Inflammation with esophageal food impaction in adults. Gastrointest Endosc 2005; 61: 795-801. (Pubitemid 40779406)
23. Potter JW, Saeian K, Staff D et al. Eosinophilic esophagitis in adults: an emerging problem with unique esophageal features. Gastrointest Endosc 2004; 59: 355-61. (Pubitemid 38337841)
24. Fass R, Chey WD, Zakko SF et al. Clinical trial: the effects of the proton pump inhibitor dexlansoprazole MR on daytime and nighttime heartburn in patients with non-erosive reflux disease. Aliment Pharmacol Ther 2009; 29: 1261-72.
25. Richter JE, Kovacs TO, Greski-Rose PA et al. Lansoprazole in the treatment of heartburn in patients without erosive oesophagitis. Aliment Pharmacol Ther 1999; 13: 795-804. (Pubitemid 29276850)
26. Hetzel DJ, Dent J, Reed WD et al. Healing and relapse of severe peptic esophagitis aft er treatment with omeprazole. Gastroenterology 1988; 95: 903-12.
27. Gerson LB, Ullah N, Hastie T et al. Patient-derived health state utilities for gastroesophageal reflux disease. Am J Gastroenterol 2005; 100: 524-33. (Pubitemid 40487547)
28. Arora AS, Perrault J, Smyrk TC. Topical corticosteroid treatment of dysphagia due to eosinophilic esophagitis in adults. Mayo Clin Proc 2003; 78: 830-5. (Pubitemid 36759291)
29. Sgouros SN, Bergele C, Mantides A. Eosinophilic esophagitis in adults: a systematic review. Eur J Gastroenterol Hepatol 2006; 18: 211-7. (Pubitemid 43361608)
30. Liacouras CA, Spergel JM, Ruchelli E et al. Eosinophilic esophagitis: a 10-year experience in 381 children. Clin Gastroenterol Hepatol 2005; 3: 1198-206. (Pubitemid 41797671)
31. Croese J, Fairley SK, Masson JW et al. Clinical and endoscopic features of eosinophilic esophagitis in adults. Gastrointest Endosc 2003; 58: 516-22. (Pubitemid 37205763)
32. Ngo P, Furuta GT, Antonioli DA et al. Eosinophils in the esophagus-peptic or allergic eosinophilic esophagitis? Case series of three patients with esophageal eosinophilia. Am J Gastroenterol 2006; 101 : 1666-70.
33. Spechler SJ, Genta RM, Souza RF. Th oughts on the complex relationship between gastroesophageal reflux disease and eosinophilic esophagitis. Am J Gastroenterol 2007; 102: 1301-6. (Pubitemid 46802025)
34. Aceves SS, Ackerman SJ. Relationships between eosinophilic Inflammation, tissue remodeling, and fibrosis in eosinophilic esophagitis. Immunol Allergy Clin North Am 2009; 29: 197-211, xiii-xiv.
35. Jacobs Jr JW, Spechler SJ. A systematic review of the risk of perforation during esophageal dilation for patients with eosinophilic esophagitis. Dig Dis Sci 2010; 55: 1512-5.
36. Fujiwara Y, Higuchi K, Nebiki H et al. Famotidine vs. omeprazole: a prospective randomized multicentre trial to determine efficacy in non-erosive gastrooesophageal reflux disease. Aliment Pharmacol Ther 2005; 21 (Suppl 2): 10-8. (Pubitemid 40806575)
37. Scholten T, Teutsch I, Bohuschke M et al. Pantoprazole on-demand effectively treats symptoms in patients with gastro-oesophageal reflux disease. Clin Drug Investig 2007; 27: 287-96. (Pubitemid 46440301)
38. Schaefer ET, Fitzgerald JF, Molleston JP et al. Comparison of oral prednisone and topical fluticasone in the treatment of eosinophilic esophagitis: a randomized trial in children. Clin Gastroenterol Hepatol 2008; 6: 165-73. (Pubitemid 351172942)
39. Peterson KA, Thomas KL, Hilden K et al. Comparison of esomeprazole to aerosolized, swallowed fluticasone for eosinophilic esophagitis. Dig Dis Sci 2010; 55: 1313-9.
40. Alexander JJK, Arora A, Enders F et al. A randomized placebo-controlled trial of swallowed fluticasone as treatment for eosinophilic esophagitis. Am J Gatroenterol 2010; 105: S21.